An Open-Label Pilot Study Evaluating by Magnetic Resonance Imaging the Potential for a Disease-Modifying Effect of Celecoxib Compared to a Modelized Historical Control Cohort in the Treatment of Knee Osteoarthritis

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 3, 2010, Pages 185-192

  Raynauld, Jean Pierre ^a   Martel Pelletier, Johanne ^a   Beaulieu, André ^b   Bessette, Louis ^c   Morin, Frédéric ^d   Choquette, Denis ^a   Haraoui, Boulos ^a   Abram, François ^e   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Groupe de Recherche en Rhumatologie et Maladies Osseuses   (Canada)

^d Centre de Recherche Musculo squelettique   (Canada)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Cartilage loss; Cohort study; Modelization; Quantitative MRI

Indexed keywords

CELECOXIB;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BIOLOGICAL MODEL; BLOOD PRESSURE; BONE MARROW EDEMA; BREAST CANCER; BRONCHITIS; CLINICAL TRIAL; COHORT ANALYSIS; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FEMUR CONDYLE; GASTROINTESTINAL DISEASE; HEART FAILURE; HEART INFARCTION; HUMAN; JOINT STIFFNESS; KNEE MENISCUS RUPTURE; KNEE OSTEOARTHRITIS; KNEE PAIN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PERIPHERAL EDEMA; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SIDE EFFECT; TIBIA; UPPER RESPIRATORY TRACT INFECTION;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARTILAGE, ARTICULAR; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPEPSIA; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; LINEAR MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PILOT PROJECTS; PYRAZOLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 78649452031     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2009.10.003     Document Type: Article

References (27)

1. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
2. Moore R.A., Derry S., Makinson G.T., McQuay H.J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther 2005, 7:R644-R665.
3. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 2007, 15:981-1000.
4. Tindall E.A., Sharp J.T., Burr A., Katz T.K., Wallemark C.B., Verburg K., et al. A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther 2002, 24:2051-2063.
5. Mastbergen S.C., Lafeber F.P., Bijlsma J.W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 2002, 41:801-808.
6. Raynauld J.-P., Martel-Pelletier J., Bias P., Laufer S., Haraoui B., Choquette D., et al. Protective effects of licofelone, a 5-lipoxygenase and cyclooxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis 2009, 68:938-947.
7. Raynauld J.P., Martel-Pelletier J., Berthiaume M.J., Labonté F., Beaudoin G., de Guise J.A., et al. Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over 2 years and correlation with clinical symptoms and radiologic changes. Arthritis Rheum 2004, 50:476-487.
8. Bingham C.O., Buckland-Wright J.C., Garnero P., Cohen S.B., Dougados M., Adami S., et al. Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the 2-year multinational knee osteoarthritis structural arthritis study. Arthritis Rheum 2006, 54:3494-3507.
9. Raynauld J.P., Martel-Pelletier J., Berthiaume M.J., Beaudoin G., Choquette D., Haraoui B., et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 2006, 8:R21.
10. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005, 52:3403-3412.
11. Listing J., Strangfeld A., Rau R., Kekow J., Gromnica-Ihle E., Klopsch T., et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 2006, 8:R66.
12. Carmona L., Descalzo M.A., Perez-Pampin E., Ruiz-Montesinos D., Erra A., Cobo T., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885.
13. Lunt M., Solomon D., Rothman K., Glynn R., Hyrich K., Symmons D.P., et al. Different methods of balancing covariates leading to different effect estimates in the presence of effect modification. Am J Epidemiol 2009, 169:909-917.
14. Altman R.D., Asch E., Bloch D.A., Bole G., Borenstein D., Brandt K.D., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986, 29:1039-1049.
15. Kellgren J.H., Lawrence J.S. Radiological assessment of osteoarthosis. Ann Rheum Dis 1957, 16:494-502.
16. Kauffmann C., Gravel P., Godbout B., Gravel A., Beaudoin G., Raynauld J.-P., et al. Computer-aided method for quantification of cartilage thickness and volume changes using MRI: validation study using a synthetic model. IEEE Trans Biomed Eng 2003, 50:978-988.
17. Felson D.T., McLaughlin S., Goggins J., LaValley M.P., Gale M.E., Totterman S., et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003, 139:330-336.
18. Berthiaume M.J., Raynauld J.P., Martel-Pelletier J., Labonté F., Beaudoin G., Bloch D.A., et al. Meniscal tear and extrusion are strongly associated with the progression of knee osteoarthritis as assessed by quantitative magnetic resonance imaging. Ann Rheum Dis 2005, 64:556-563.
19. Hunter D.J., Zhang Y., Niu J., Goggins J., Amin S., LaValley M.P., et al. Increase in bone marrow lesions associated with cartilage loss: a longitudinal magnetic resonance imaging study of knee osteoarthritis. Arthritis Rheum 2006, 54:1529-1535.
20. Raynauld J.-P., Martel-Pelletier J., Berthiaume M.-J., Abram F., Choquette D., Haraoui B., et al. Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period. Ann Rheum Dis 2008, 67:683-688.
21. Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a 3-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 2001, 44:2539-2547.
22. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001, 357:251-256.
23. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002, 162:2113-2123.
24. Brandt K.D., Mazzuca S.A. Lessons learned from 9 clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum 2005, 52:3349-3359.
25. Cicuttini F.M., Wluka A.E., Stuckey S.L. Tibial and femoral cartilage changes in knee osteoarthritis. Ann Rheum Dis 2001, 60:977-980.
26. Wluka A.E., Wolfe R., Stuckey S., Cicuttini F.M. How does tibial cartilage volume relate to symptoms in subjects with knee osteoarthritis?. Ann Rheum Dis 2004, 63:264-268.
27. Huskisson E.C., Berry H., Gishen P., Jubb R.W., Whitehead J. Effects of antiinflammatory drugs on the progression of osteoarthritis of the knee. LINK Study Group Longitudinal Investigation of Nonsteroidal Antiinflammatory Drugs in Knee Osteoarthritis. J Rheumatol 1995, 22:1941-1946.